BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 21416507)

  • 1. Haematological toxicity of clozapine and some other drugs used in psychiatry.
    Nooijen PM; Carvalho F; Flanagan RJ
    Hum Psychopharmacol; 2011 Mar; 26(2):112-9. PubMed ID: 21416507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Haematological toxicity of drugs used in psychiatry.
    Flanagan RJ; Dunk L
    Hum Psychopharmacol; 2008 Jan; 23 Suppl 1():27-41. PubMed ID: 18098216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term patient monitoring for clozapine-induced agranulocytosis and neutropenia in Korea: when is it safe to discontinue CPMS?
    Kang BJ; Cho MJ; Oh JT; Lee Y; Chae BJ; Ko J
    Hum Psychopharmacol; 2006 Aug; 21(6):387-91. PubMed ID: 16933201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A case study; ethnicity and clozapine, a risky combination?].
    Laan WJ; Ramlal D
    Tijdschr Psychiatr; 2012; 54(9):829-33. PubMed ID: 22961282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clozapine: the commitment to patient safety.
    Alphs LD; Anand R
    J Clin Psychiatry; 1999; 60 Suppl 12():39-42. PubMed ID: 10372610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of complete blood count sampling time change on white blood cell and absolute neutrophil count values in clozapine recipients.
    McKee JR; Wall T; Owensby J
    Clin Schizophr Relat Psychoses; 2011 Apr; 5(1):26-32. PubMed ID: 21459736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Haematological side effects of clozapine: patient characteristics.
    Miller PR; Cutten AE
    N Z Med J; 1997 Apr; 110(1041):125-7. PubMed ID: 9140414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring.
    Schulte P
    Ann Pharmacother; 2006 Apr; 40(4):683-8. PubMed ID: 16595571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Granulocytopenia while using clozapine: continuing or stopping treatment].
    Bogers JP
    Tijdschr Psychiatr; 2007; 49(8):575-9. PubMed ID: 17694491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hematological adverse events in clozapine-treated children and adolescents.
    Gerbino-Rosen G; Roofeh D; Tompkins DA; Feryo D; Nusser L; Kranzler H; Napolitano B; Frederickson A; Henderson I; Rhinewine J; Kumra S
    J Am Acad Child Adolesc Psychiatry; 2005 Oct; 44(10):1024-31. PubMed ID: 16175107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clozapine rechallenge after neutropenia in resistant schizophrenia: A review].
    Simon L; Cazard F
    Encephale; 2016 Aug; 42(4):346-53. PubMed ID: 27109327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paradoxical pattern of haematological risk with clozapine.
    Gillman K
    Br J Psychiatry; 2000 Jul; 177():88. PubMed ID: 10945101
    [No Abstract]   [Full Text] [Related]  

  • 13. Clozapine, agranulocytosis, and benign ethnic neutropenia.
    Rajagopal S
    Postgrad Med J; 2005 Sep; 81(959):545-6. PubMed ID: 16143678
    [No Abstract]   [Full Text] [Related]  

  • 14. Clozapine-induced neutropenia in children: management with lithium carbonate.
    Sporn A; Gogtay N; Ortiz-Aguayo R; Alfaro C; Tossell J; Lenane M; Gochman P; Rapoport JL
    J Child Adolesc Psychopharmacol; 2003; 13(3):401-4. PubMed ID: 14642024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lithium and clozapine rechallenge: a retrospective case analysis.
    Kanaan RA; Kerwin RW
    J Clin Psychiatry; 2006 May; 67(5):756-60. PubMed ID: 16841625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Restarting clozapine after neutropenia: evaluating the possibilities and practicalities.
    Whiskey E; Taylor D
    CNS Drugs; 2007; 21(1):25-35. PubMed ID: 17190527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does switching to another antipsychotic in patients with clozapine-associated granulocytopenia solve the problem? Case series of 18 patients.
    Coşar B; Taner ME; Eser HY; Altınöz AE; Tarhan R
    J Clin Psychopharmacol; 2011 Apr; 31(2):169-73. PubMed ID: 21346615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of clozapine safety.
    Fitzsimons J; Berk M; Lambert T; Bourin M; Dodd S
    Expert Opin Drug Saf; 2005 Jul; 4(4):731-44. PubMed ID: 16011451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A case of agranulocytosis secondary to rechallenge with clozapine following severe neutropenia during previous therapy.
    Lertxundi U; Sanchez P; Hernandez R; Elizagarate E
    J Clin Psychiatry; 2011 Dec; 72(12):1659. PubMed ID: 22244024
    [No Abstract]   [Full Text] [Related]  

  • 20. Clozapine treatment after agranulocytosis induced by classic neuroleptics.
    Bauer M; Mackert A
    J Clin Psychopharmacol; 1994 Feb; 14(1):71-3. PubMed ID: 7908676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.